Candriam S.C.A. Takes $9.49 Million Position in Sionna Therapeutics, Inc. $SION

Candriam S.C.A. purchased a new stake in shares of Sionna Therapeutics, Inc. (NASDAQ:SION) during the first quarter, Holdings Channel.com reports. The fund purchased 236,813 shares of the company’s stock, valued at approximately $9,494,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in SION. Goldman Sachs Group Inc. bought a new stake in Sionna Therapeutics in the 1st quarter worth about $667,000. Woodline Partners LP purchased a new stake in Sionna Therapeutics in the 1st quarter valued at about $837,000. Geode Capital Management LLC lifted its position in shares of Sionna Therapeutics by 113.4% during the 2nd quarter. Geode Capital Management LLC now owns 289,275 shares of the company’s stock worth $5,020,000 after buying an additional 153,712 shares in the last quarter. Rhumbline Advisers purchased a new position in shares of Sionna Therapeutics in the 2nd quarter worth approximately $307,000. Finally, New York State Common Retirement Fund purchased a new position in shares of Sionna Therapeutics in the 2nd quarter worth approximately $118,000.

Analysts Set New Price Targets

SION has been the subject of a number of research analyst reports. JonesTrading increased their price target on Sionna Therapeutics from $52.00 to $63.00 and gave the company a “buy” rating in a research report on Tuesday, April 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Sionna Therapeutics in a research report on Friday, May 8th. Stifel Nicolaus upped their price objective on Sionna Therapeutics from $44.00 to $55.00 and gave the company a “buy” rating in a research note on Monday, May 18th. Citizens Jmp reaffirmed a “market outperform” rating and set a $63.00 target price on shares of Sionna Therapeutics in a research report on Tuesday, May 26th. Finally, BTIG Research reiterated a “buy” rating and set a $58.00 target price on shares of Sionna Therapeutics in a research note on Wednesday, May 13th. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $53.22.

Insiders Place Their Bets

In other Sionna Therapeutics news, Director Orbimed Advisors Llc sold 85,918 shares of the firm’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total transaction of $3,854,281.48. Following the sale, the director owned 2,469,959 shares in the company, valued at $110,802,360.74. This trade represents a 3.36% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 85,918 shares of Sionna Therapeutics stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $44.86, for a total value of $3,854,281.48. Following the sale, the director directly owned 2,469,959 shares of the company’s stock, valued at approximately $110,802,360.74. This trade represents a 3.36% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 2,121,486 shares of company stock valued at $95,822,256 over the last ninety days. 5.10% of the stock is currently owned by insiders.

Sionna Therapeutics Stock Performance

Shares of SION opened at $45.29 on Monday. The company has a market cap of $2.04 billion, a PE ratio of -23.47 and a beta of 1.33. The stock has a 50-day moving average price of $40.44 and a 200-day moving average price of $39.56. Sionna Therapeutics, Inc. has a 12-month low of $16.38 and a 12-month high of $48.44.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings results on Tuesday, May 12th. The company reported ($0.60) EPS for the quarter, missing analysts’ consensus estimates of ($0.52) by ($0.08). As a group, analysts predict that Sionna Therapeutics, Inc. will post -2.57 earnings per share for the current year.

Sionna Therapeutics Company Profile

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.